Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2009: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Research Abstract |
Acyclic retinoid, a synthetic retinoid targeting RXR., prevented the recurrence of hepatocellular carcinoma(HCC) in hepatitis C virus-positive patients in a phase II/III clinical trial. This agent also inhibits obesity-related liver tumorigenesis and acts synergistically with valproic acid, GW4064, a FXR ligand, and branched-chain amino acids in suppressing growth in human HCC cells, indicating that "combination chemoprevention" with acyclic retinoid as the key drug has great potential to become an effective strategy for the prevention of liver carcinogenesis.
|